National utilization of regional lymph node dissection among patients with kidney cancer and clinical lymphadenopathy undergoing radical nephrectomy

Robert Abouassaly, Matthew J. Bream, Marc C. Smaldone, Alexander Kutikov, Nilay D Shah, Christopher M. Gonzalez, Stephen B. Williams, Robert Houston Thompson, Stephen A. Boorjian, Simon P. Kim

Research output: Contribution to journalArticle

Abstract

Introduction/background Regional lymph node dissection (LND) may provide oncologic benefit among patients with clinical lymphadenopathy in renal cell carcinoma (RCC) at the of time radical nephrectomy (RN). Yet, little is known about contemporary use of LND for patients with RCC and regional lymphadenopathy. Thus, we assessed national trends in RN and LND among RCC patients with renal masses and clinical lymphadenopathy. Materials and methods From the National Cancer Data Base (NCDB), we identified patients with RCC and clinical lymphadenopathy without distant metastasis (clinical T1-4 N1+ M0) who underwent RN from 2001 to 2011. The primary outcome was concomitant LND at the time of RN. Multivariable logistic regression analysis was used to identify patient and hospital characteristics associated with the primary outcome. Results Among 1840 patients with clinical N1+ treated surgically, 78% received LND (n=1444). The proportion of patients who underwent LND increased from 77% in 2001 to 82% in 2011 (p<0.01 for trend). On multivariable analysis, patients undergoing surgery at academic centers were more likely to undergo LND compared to those treated at community hospitals (OR: 1.59; p<0.01). In a subset of patients with surgical approach available, robotic or laparoscopic nephrectomy also correlated with lower use of RN and LND compared to open surgery (OR: 0.46; p<0.01). Conclusion Among patients with RCC and clinical lymphadenopathy, ~20% are not receiving LND at the time of RN in the U.S. Academic hospitals and open surgery was associated with receipt of LND. Centralization to tertiary academic hospitals may facilitate greater use of LND.

Original languageEnglish (US)
Pages (from-to)14-18
Number of pages5
JournalCancer Treatment and Research Communications
Volume12
DOIs
StatePublished - 2017

Fingerprint

Kidney Neoplasms
Lymph Node Excision
Nephrectomy
Renal Cell Carcinoma
Lymphadenopathy
Community Hospital
Robotics
Tertiary Care Centers
Logistic Models
Regression Analysis
Databases
Neoplasm Metastasis
Kidney

Keywords

  • Clinical lymphadenopathy
  • Kidney cancer
  • Lymph node dissection
  • Nephrectomy
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

National utilization of regional lymph node dissection among patients with kidney cancer and clinical lymphadenopathy undergoing radical nephrectomy. / Abouassaly, Robert; Bream, Matthew J.; Smaldone, Marc C.; Kutikov, Alexander; Shah, Nilay D; Gonzalez, Christopher M.; Williams, Stephen B.; Thompson, Robert Houston; Boorjian, Stephen A.; Kim, Simon P.

In: Cancer Treatment and Research Communications, Vol. 12, 2017, p. 14-18.

Research output: Contribution to journalArticle

Abouassaly, Robert ; Bream, Matthew J. ; Smaldone, Marc C. ; Kutikov, Alexander ; Shah, Nilay D ; Gonzalez, Christopher M. ; Williams, Stephen B. ; Thompson, Robert Houston ; Boorjian, Stephen A. ; Kim, Simon P. / National utilization of regional lymph node dissection among patients with kidney cancer and clinical lymphadenopathy undergoing radical nephrectomy. In: Cancer Treatment and Research Communications. 2017 ; Vol. 12. pp. 14-18.
@article{e835ea78240f419e9fca5f119d069c3c,
title = "National utilization of regional lymph node dissection among patients with kidney cancer and clinical lymphadenopathy undergoing radical nephrectomy",
abstract = "Introduction/background Regional lymph node dissection (LND) may provide oncologic benefit among patients with clinical lymphadenopathy in renal cell carcinoma (RCC) at the of time radical nephrectomy (RN). Yet, little is known about contemporary use of LND for patients with RCC and regional lymphadenopathy. Thus, we assessed national trends in RN and LND among RCC patients with renal masses and clinical lymphadenopathy. Materials and methods From the National Cancer Data Base (NCDB), we identified patients with RCC and clinical lymphadenopathy without distant metastasis (clinical T1-4 N1+ M0) who underwent RN from 2001 to 2011. The primary outcome was concomitant LND at the time of RN. Multivariable logistic regression analysis was used to identify patient and hospital characteristics associated with the primary outcome. Results Among 1840 patients with clinical N1+ treated surgically, 78{\%} received LND (n=1444). The proportion of patients who underwent LND increased from 77{\%} in 2001 to 82{\%} in 2011 (p<0.01 for trend). On multivariable analysis, patients undergoing surgery at academic centers were more likely to undergo LND compared to those treated at community hospitals (OR: 1.59; p<0.01). In a subset of patients with surgical approach available, robotic or laparoscopic nephrectomy also correlated with lower use of RN and LND compared to open surgery (OR: 0.46; p<0.01). Conclusion Among patients with RCC and clinical lymphadenopathy, ~20{\%} are not receiving LND at the time of RN in the U.S. Academic hospitals and open surgery was associated with receipt of LND. Centralization to tertiary academic hospitals may facilitate greater use of LND.",
keywords = "Clinical lymphadenopathy, Kidney cancer, Lymph node dissection, Nephrectomy, Renal cell carcinoma",
author = "Robert Abouassaly and Bream, {Matthew J.} and Smaldone, {Marc C.} and Alexander Kutikov and Shah, {Nilay D} and Gonzalez, {Christopher M.} and Williams, {Stephen B.} and Thompson, {Robert Houston} and Boorjian, {Stephen A.} and Kim, {Simon P.}",
year = "2017",
doi = "10.1016/j.ctarc.2017.05.001",
language = "English (US)",
volume = "12",
pages = "14--18",
journal = "Cancer Treatment and Research Communications",
issn = "2213-0896",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - National utilization of regional lymph node dissection among patients with kidney cancer and clinical lymphadenopathy undergoing radical nephrectomy

AU - Abouassaly, Robert

AU - Bream, Matthew J.

AU - Smaldone, Marc C.

AU - Kutikov, Alexander

AU - Shah, Nilay D

AU - Gonzalez, Christopher M.

AU - Williams, Stephen B.

AU - Thompson, Robert Houston

AU - Boorjian, Stephen A.

AU - Kim, Simon P.

PY - 2017

Y1 - 2017

N2 - Introduction/background Regional lymph node dissection (LND) may provide oncologic benefit among patients with clinical lymphadenopathy in renal cell carcinoma (RCC) at the of time radical nephrectomy (RN). Yet, little is known about contemporary use of LND for patients with RCC and regional lymphadenopathy. Thus, we assessed national trends in RN and LND among RCC patients with renal masses and clinical lymphadenopathy. Materials and methods From the National Cancer Data Base (NCDB), we identified patients with RCC and clinical lymphadenopathy without distant metastasis (clinical T1-4 N1+ M0) who underwent RN from 2001 to 2011. The primary outcome was concomitant LND at the time of RN. Multivariable logistic regression analysis was used to identify patient and hospital characteristics associated with the primary outcome. Results Among 1840 patients with clinical N1+ treated surgically, 78% received LND (n=1444). The proportion of patients who underwent LND increased from 77% in 2001 to 82% in 2011 (p<0.01 for trend). On multivariable analysis, patients undergoing surgery at academic centers were more likely to undergo LND compared to those treated at community hospitals (OR: 1.59; p<0.01). In a subset of patients with surgical approach available, robotic or laparoscopic nephrectomy also correlated with lower use of RN and LND compared to open surgery (OR: 0.46; p<0.01). Conclusion Among patients with RCC and clinical lymphadenopathy, ~20% are not receiving LND at the time of RN in the U.S. Academic hospitals and open surgery was associated with receipt of LND. Centralization to tertiary academic hospitals may facilitate greater use of LND.

AB - Introduction/background Regional lymph node dissection (LND) may provide oncologic benefit among patients with clinical lymphadenopathy in renal cell carcinoma (RCC) at the of time radical nephrectomy (RN). Yet, little is known about contemporary use of LND for patients with RCC and regional lymphadenopathy. Thus, we assessed national trends in RN and LND among RCC patients with renal masses and clinical lymphadenopathy. Materials and methods From the National Cancer Data Base (NCDB), we identified patients with RCC and clinical lymphadenopathy without distant metastasis (clinical T1-4 N1+ M0) who underwent RN from 2001 to 2011. The primary outcome was concomitant LND at the time of RN. Multivariable logistic regression analysis was used to identify patient and hospital characteristics associated with the primary outcome. Results Among 1840 patients with clinical N1+ treated surgically, 78% received LND (n=1444). The proportion of patients who underwent LND increased from 77% in 2001 to 82% in 2011 (p<0.01 for trend). On multivariable analysis, patients undergoing surgery at academic centers were more likely to undergo LND compared to those treated at community hospitals (OR: 1.59; p<0.01). In a subset of patients with surgical approach available, robotic or laparoscopic nephrectomy also correlated with lower use of RN and LND compared to open surgery (OR: 0.46; p<0.01). Conclusion Among patients with RCC and clinical lymphadenopathy, ~20% are not receiving LND at the time of RN in the U.S. Academic hospitals and open surgery was associated with receipt of LND. Centralization to tertiary academic hospitals may facilitate greater use of LND.

KW - Clinical lymphadenopathy

KW - Kidney cancer

KW - Lymph node dissection

KW - Nephrectomy

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85027501122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027501122&partnerID=8YFLogxK

U2 - 10.1016/j.ctarc.2017.05.001

DO - 10.1016/j.ctarc.2017.05.001

M3 - Article

VL - 12

SP - 14

EP - 18

JO - Cancer Treatment and Research Communications

JF - Cancer Treatment and Research Communications

SN - 2213-0896

ER -